Jin Kyeong Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jin Kyeong Choi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ha Eun Kim
Department of Immunology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea
4 shared publications - Jong Yeong Lee
Department of Immunology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea
4 shared publications - Jin Park
Department of Dermatology, College of Medicine, Jeonbuk National University, Jeonju, Korea
3 shared publications Jong Yeong Lee
Department of Immunology, Jeonbuk National University Medical School, Jeonju, 54907, Republic of Korea
3 shared publicationsJun-Young Park
Department of Biochemistry, Chungbuk National University, Cheongju, 28644, Republic of Korea
3 shared publications- Jun-Young Park
Department of Biochemistry, Chungbuk National University, Cheongju 28644, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1500
Limonin Attenuates Atopic Dermatitis-like Inflammation and Alters Mitochondrial Readouts and AMPK-mTOR-Associated Signaling in Keratinocytes
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with mitochondrial oxidative stress and metabolic dysregulation. This study investigated the anti-inflammatory effects of limonin and the accompanying changes in selected mitochondrial parameters and metabolic signaling. In female C57BL/6 mice with MC903-induced atopic dermatitis-like skin inflammation, limonin reduced epidermal hyperplasia, dermal thickening, and inflammatory cytokine expression and lowered the proportions of inflammatory myeloid cells in ear skin. Limonin also suppressed Th1 and Th2 responses and altered regulatory T-cell frequencies. These effects were accompanied by a lower proportion of MitoTracker+MitoSOX+ cells, a higher proportion of MitoTracker+TMRM+ cells, and increased abundance of selected respiratory chain proteins. In IL-4/IL-13-stimulated human primary keratinocytes, limonin suppressed inflammatory chemokines and epithelial cytokines while decreasing the proportion of MitoTracker+MitoSOX+ cells and increasing the proportion of MitoTracker+TMRM+ cells. Limonin reduced the proportion of 2-NBDG-positive cells and lowered GLUT1 mRNA levels. It also increased maximal mitochondrial respiration and the abundance of selected oxidative phosphorylation subunits. These changes were accompanied by increased AMPKα Thr172 phosphorylation and decreased phosphorylation of mTOR at Ser2448, RICTOR at Thr1135, AKT at Ser473, and FOXO3a at Ser253. Cellular thermal shift assays revealed changes in mTOR and AMPKα thermal stability following limonin treatment. Limonin attenuated experimental AD-like skin inflammation and reduced inflammatory responses in cytokine-stimulated human keratinocytes, with accompanying changes in selected mitochondrial parameters and AMPK-mTOR-associated phosphorylation.
- 18 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1500
Open AccessLimonin Attenuates Atopic Dermatitis-like Inflammation and Alters Mitochondrial Readouts and AMPK-mTOR-Associated Signaling in Keratinocytes
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with mitochondrial oxidative stress and metabolic dysregulation. This study investigated the anti-inflammatory effects of limonin and the accompanying changes in selected mitochondrial parameters and metabolic signaling. In female C57BL/6 mice with MC903-induced atopic dermatitis-like skin inflammation, limonin reduced epidermal hyperplasia, dermal thickening, and inflammatory cytokine expression and lowered the proportions of inflammatory myeloid cells in ear skin. Limonin also suppressed Th1 and Th2 responses and altered regulatory T-cell frequencies. These effects were accompanied by a lower proportion of MitoTracker+MitoSOX+ cells, a higher proportion of MitoTracker+TMRM+ cells, and increased abundance of selected respiratory chain proteins. In IL-4/IL-13-stimulated human primary keratinocytes, limonin suppressed inflammatory chemokines and epithelial cytokines while decreasing the proportion of MitoTracker+MitoSOX+ cells and increasing the proportion of MitoTracker+TMRM+ cells. Limonin reduced the proportion of 2-NBDG-positive cells and lowered GLUT1 mRNA levels. It also increased maximal mitochondrial respiration and the abundance of selected oxidative phosphorylation subunits. These changes were accompanied by increased AMPKα Thr172 phosphorylation and decreased phosphorylation of mTOR at Ser2448, RICTOR at Thr1135, AKT at Ser473, and FOXO3a at Ser253. Cellular thermal shift assays revealed changes in mTOR and AMPKα thermal stability following limonin treatment. Limonin attenuated experimental AD-like skin inflammation and reduced inflammatory responses in cytokine-stimulated human keratinocytes, with accompanying changes in selected mitochondrial parameters and AMPK-mTOR-associated phosphorylation.
- 4 September 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
Eschar in scrub typhus: clinical signature, immunopathogenesis, and diagnostic implications
SUMMARY: Scrub typhus, caused by Orientia tsutsugamushi , remains a major cause of acute undifferentiated febrile illness with an expanding global footprint. Early diagnosis is frequently delayed because of nonspecific systemic manifestations and geographic heterogeneity. The eschar, traditionally regarded as a characteristic but unreliable clinical sign, is better understood as a dynamic and biologically active lesion rather than a static cutaneous finding. Accumulating clinical, epidemiologic, and pathologic evidence demonstrates that eschar morphology and detectability vary widely with timing, anatomical location, host factors, and prior exposure, whereas its presence does not predict disease severity. Importantly, the eschar represents the primary site of pathogen inoculation, local amplification, and lymphatic dissemination preceding systemic endothelial infection. This biology has direct diagnostic implications: minimally invasive eschar swab-based molecular diagnostics consistently outperform blood-based assays during the early stages of illness and provide an optimal platform for emerging technologies. Furthermore, early eschar-based recognition dictates the timely initiation of targeted antimicrobial therapy, optimizing standard regimens and guiding safe treatment in vulnerable populations, while highlighting the need for novel therapeutics against drug-resistant strains. Reframing the eschar as a central clinical, diagnostic, and therapeutic axis offers a coherent framework for improving early recognition and future management strategies in scrub typhus.
- 4 September 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
Eschar in scrub typhus: clinical signature, immunopathogenesis, and diagnostic implications
SUMMARY: Scrub typhus, caused by Orientia tsutsugamushi , remains a major cause of acute undifferentiated febrile illness with an expanding global footprint. Early diagnosis is frequently delayed because of nonspecific systemic manifestations and geographic heterogeneity. The eschar, traditionally regarded as a characteristic but unreliable clinical sign, is better understood as a dynamic and biologically active lesion rather than a static cutaneous finding. Accumulating clinical, epidemiologic, and pathologic evidence demonstrates that eschar morphology and detectability vary widely with timing, anatomical location, host factors, and prior exposure, whereas its presence does not predict disease severity. Importantly, the eschar represents the primary site of pathogen inoculation, local amplification, and lymphatic dissemination preceding systemic endothelial infection. This biology has direct diagnostic implications: minimally invasive eschar swab-based molecular diagnostics consistently outperform blood-based assays during the early stages of illness and provide an optimal platform for emerging technologies. Furthermore, early eschar-based recognition dictates the timely initiation of targeted antimicrobial therapy, optimizing standard regimens and guiding safe treatment in vulnerable populations, while highlighting the need for novel therapeutics against drug-resistant strains. Reframing the eschar as a central clinical, diagnostic, and therapeutic axis offers a coherent framework for improving early recognition and future management strategies in scrub typhus.
- 7 July 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (5) , 1333-1346
AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis
- 7 July 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (5) , 1333-1346
AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (2) , 1023-1044
Accelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis
Background: Osteoarthritis (OA) is a prevalent and debilitating chronic disease for which there are currently no approved disease-modifying osteoarthritis drugs (DMOADs). While mesenchymal stem cells (MSCs) have emerged as promising DMOAD candidates, their clinical application is hindered by inconsistent in vivo efficacy and an incomplete understanding of the underlying pathological mechanisms and therapeutic targets.
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (2) , 1023-1044
Top Cited PapersOpen AccessAccelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis
Background: Osteoarthritis (OA) is a prevalent and debilitating chronic disease for which there are currently no approved disease-modifying osteoarthritis drugs (DMOADs). While mesenchymal stem cells (MSCs) have emerged as promising DMOAD candidates, their clinical application is hindered by inconsistent in vivo efficacy and an incomplete understanding of the underlying pathological mechanisms and therapeutic targets.
- Open Access
- 24 April 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (5) , 512
Nitazoxanide Modulates Mitochondrial Function and Inflammatory Metabolism in Chondrocytes from Patients with Osteoarthritis via AMPK/mTORC1 Signaling
Osteoarthritis (OA) is a long-term degenerative condition of the joints, characterized by persistent inflammation, progressive cartilage breakdown, and impaired mitochondrial function. Recent studies have shown that hyperactivation of the mTORC1 pathway and metabolic reprogramming of chondrocytes contribute to disease progression. Nitazoxanide (NTZ), an oral antiparasitic agent approved by the Food and Drug Administration, has shown anti-inflammatory and mitochondrial protective effects in various disease situations; despite this, its application in osteoarthritis has yet to be fully investigated. Here, we assessed the therapeutic efficacy of NTZ using IL-1β-stimulated primary chondrocytes derived from patients with OA. NTZ substantially reduced the expression of proinflammatory cytokines and matrix metalloproteinases, restored mitochondrial membrane potential, and reduced mitochondrial reactive oxygen species levels. NTZ also effectively reversed IL-1β-induced glycolytic metabolic changes by inhibiting glucose uptake and GLUT1 expression. Mechanistically, NTZ inhibited the activation of the mTORC1 pathway and substantially increased AMPK phosphorylation. The siRNA-mediated AMPK knockdown negated NTZ-induced mitochondrial and metabolic improvements, suggesting that AMPK is a key upstream regulator of the protective actions of NTZ. NTZ can, therefore, effectively inhibit inflammatory metabolic reprogramming and mitochondrial dysfunction in OA chondrocytes through AMPK-dependent mTORC1 signaling inhibition, highlighting its potential as a disease-modifying therapy for OA.
- 24 April 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (5) , 512
Open AccessNitazoxanide Modulates Mitochondrial Function and Inflammatory Metabolism in Chondrocytes from Patients with Osteoarthritis via AMPK/mTORC1 Signaling
Osteoarthritis (OA) is a long-term degenerative condition of the joints, characterized by persistent inflammation, progressive cartilage breakdown, and impaired mitochondrial function. Recent studies have shown that hyperactivation of the mTORC1 pathway and metabolic reprogramming of chondrocytes contribute to disease progression. Nitazoxanide (NTZ), an oral antiparasitic agent approved by the Food and Drug Administration, has shown anti-inflammatory and mitochondrial protective effects in various disease situations; despite this, its application in osteoarthritis has yet to be fully investigated. Here, we assessed the therapeutic efficacy of NTZ using IL-1β-stimulated primary chondrocytes derived from patients with OA. NTZ substantially reduced the expression of proinflammatory cytokines and matrix metalloproteinases, restored mitochondrial membrane potential, and reduced mitochondrial reactive oxygen species levels. NTZ also effectively reversed IL-1β-induced glycolytic metabolic changes by inhibiting glucose uptake and GLUT1 expression. Mechanistically, NTZ inhibited the activation of the mTORC1 pathway and substantially increased AMPK phosphorylation. The siRNA-mediated AMPK knockdown negated NTZ-induced mitochondrial and metabolic improvements, suggesting that AMPK is a key upstream regulator of the protective actions of NTZ. NTZ can, therefore, effectively inhibit inflammatory metabolic reprogramming and mitochondrial dysfunction in OA chondrocytes through AMPK-dependent mTORC1 signaling inhibition, highlighting its potential as a disease-modifying therapy for OA.
- 3 March 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2495-2509.e6
The Repurposing of Nitazoxanide for Psoriasis Treatment Exerts Therapeutic Effects through Skin Metabolic Reprogramming
- 3 March 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2495-2509.e6
The Repurposing of Nitazoxanide for Psoriasis Treatment Exerts Therapeutic Effects through Skin Metabolic Reprogramming
- Open Access
- 16 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (12) , 1541
Limonin Exhibits Anti-Inflammatory Effects by Inhibiting mTORC1 and Mitochondrial Reactive Oxygen Species in Psoriatic-like Skin Inflammation
Psoriasis is a chronic inflammatory skin disorder characterized by abnormal immune responses and keratinocyte hyperproliferation. Limonin, a bioactive compound found in citrus fruits, has anti-inflammatory properties in various models; however, its effects on psoriasis are not fully understood. We investigated the therapeutic potential of limonin in a 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced psoriasis mouse model. Mice were treated with TPA to induce psoriasis-like skin lesions, followed by intraperitoneal administration of limonin (200 or 400 μg/mouse) for six days. The results showed that limonin improved psoriasis-related symptoms in a psoriasis-like mouse model by suppressing the mRNA expression of pro-inflammatory cytokines and inflammation-related antimicrobial peptides and regulating the expansion of myeloid cells and T cells. Specifically, limonin reduced glucose uptake and oxidative phosphorylation to shift the metabolic program in the inflamed skin cells of psoriasis-like mice. Limonin activates AMPK and proteins related to mTOR inhibition, thereby suppressing the mTOR signaling pathway. It also inhibits mitochondrial mass and mitochondrial ROS production, thereby preventing the development of dysfunctional mitochondria in inflamed skin cells. Overall, limonin modulates key immune responses and metabolic pathways related to inflammation and mitochondrial health in psoriasis. Therefore, it is a promising natural candidate for the treatment of psoriasis and various inflammatory skin diseases.
- 16 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (12) , 1541
Open AccessLimonin Exhibits Anti-Inflammatory Effects by Inhibiting mTORC1 and Mitochondrial Reactive Oxygen Species in Psoriatic-like Skin Inflammation
Psoriasis is a chronic inflammatory skin disorder characterized by abnormal immune responses and keratinocyte hyperproliferation. Limonin, a bioactive compound found in citrus fruits, has anti-inflammatory properties in various models; however, its effects on psoriasis are not fully understood. We investigated the therapeutic potential of limonin in a 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced psoriasis mouse model. Mice were treated with TPA to induce psoriasis-like skin lesions, followed by intraperitoneal administration of limonin (200 or 400 μg/mouse) for six days. The results showed that limonin improved psoriasis-related symptoms in a psoriasis-like mouse model by suppressing the mRNA expression of pro-inflammatory cytokines and inflammation-related antimicrobial peptides and regulating the expansion of myeloid cells and T cells. Specifically, limonin reduced glucose uptake and oxidative phosphorylation to shift the metabolic program in the inflamed skin cells of psoriasis-like mice. Limonin activates AMPK and proteins related to mTOR inhibition, thereby suppressing the mTOR signaling pathway. It also inhibits mitochondrial mass and mitochondrial ROS production, thereby preventing the development of dysfunctional mitochondria in inflamed skin cells. Overall, limonin modulates key immune responses and metabolic pathways related to inflammation and mitochondrial health in psoriasis. Therefore, it is a promising natural candidate for the treatment of psoriasis and various inflammatory skin diseases.
- Open Access
- 12 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1324026
Imidazole propionate ameliorates atopic dermatitis-like skin lesions by inhibiting mitochondrial ROS and mTORC2
Background: Imidazole propionate (IMP) is a histidine metabolite produced by some gut microorganisms in the human colon. Increased levels of IMP are associated with intestinal inflammation and the development and progression of cardiovascular disease and diabetes. However, the anti-inflammatory activity of IMP has not been investigated. This study aimed to elucidate the role of IMP in treating atopic dermatitis (AD). Methods: To understand how IMP mediates immunosuppression in AD, IMP was intraperitoneally injected into a Dermatophagoides farinae extract (DFE)/1-chloro-2,4 dinitrochlorobenzene (DNCB)-induced AD-like skin lesions mouse model. We also characterized the anti-inflammatory mechanism of IMP by inducing an AD response in keratinocytes through TNF-α/IFN-γ or IL-4 stimulation. Results: Contrary to the prevailing view that IMP is an unhealthy microbial metabolite, we found that IMP-treated AD-like skin lesions mice showed significant improvement in their clinical symptoms, including ear thickness, epidermal and dermal thickness, and IgE levels. Furthermore, IMP antagonized the expansion of myeloid (neutrophils, macrophages, eosinophils, and mast cells) and Th cells (Th1, Th2, and Th17) in mouse skin and prevented mitochondrial reactive oxygen species production by inhibiting mitochondrial energy production. Interestingly, we found that IMP inhibited AD by reducing glucose uptake in cells to suppress proinflammatory cytokines and chemokines in an AD-like in vitro model, sequentially downregulating the PI3K and mTORC2 signaling pathways centered on Akt, and upregulating DDIT4 and AMPK. Discussion: Our results suggest that IMP exerts anti-inflammatory effects through the metabolic reprogramming of skin inflammation, making it a promising therapeutic candidate for AD and related skin diseases.
- 12 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1324026
Open AccessImidazole propionate ameliorates atopic dermatitis-like skin lesions by inhibiting mitochondrial ROS and mTORC2
Background: Imidazole propionate (IMP) is a histidine metabolite produced by some gut microorganisms in the human colon. Increased levels of IMP are associated with intestinal inflammation and the development and progression of cardiovascular disease and diabetes. However, the anti-inflammatory activity of IMP has not been investigated. This study aimed to elucidate the role of IMP in treating atopic dermatitis (AD). Methods: To understand how IMP mediates immunosuppression in AD, IMP was intraperitoneally injected into a Dermatophagoides farinae extract (DFE)/1-chloro-2,4 dinitrochlorobenzene (DNCB)-induced AD-like skin lesions mouse model. We also characterized the anti-inflammatory mechanism of IMP by inducing an AD response in keratinocytes through TNF-α/IFN-γ or IL-4 stimulation. Results: Contrary to the prevailing view that IMP is an unhealthy microbial metabolite, we found that IMP-treated AD-like skin lesions mice showed significant improvement in their clinical symptoms, including ear thickness, epidermal and dermal thickness, and IgE levels. Furthermore, IMP antagonized the expansion of myeloid (neutrophils, macrophages, eosinophils, and mast cells) and Th cells (Th1, Th2, and Th17) in mouse skin and prevented mitochondrial reactive oxygen species production by inhibiting mitochondrial energy production. Interestingly, we found that IMP inhibited AD by reducing glucose uptake in cells to suppress proinflammatory cytokines and chemokines in an AD-like in vitro model, sequentially downregulating the PI3K and mTORC2 signaling pathways centered on Akt, and upregulating DDIT4 and AMPK. Discussion: Our results suggest that IMP exerts anti-inflammatory effects through the metabolic reprogramming of skin inflammation, making it a promising therapeutic candidate for AD and related skin diseases.
- Open Access
- 21 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2080-2083.e7
Decreased CD19+CD24hiCD38hi Regulatory B Cells in Alopecia Areata
- 21 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2080-2083.e7
Open AccessDecreased CD19+CD24hiCD38hi Regulatory B Cells in Alopecia Areata
- 22 December 2023
- Published by Wiley in Advanced Materials
- Vol. 36 (11) , e2304333
Inflammation‐Targeting Mesenchymal Stem Cells Combined with Photothermal Treatment Attenuate Severe Joint Inflammation
Current clinical therapeutic efficacy for the treatment of osteo‐ and rheumatoid‐arthritis is obviously limited. Although mesenchymal stem cells (MSCs) are considered as a source of promising regenerative therapy, un‐modified or genetically engineered MSCs injected in vivo restrict their clinical utility because of the low drug efficacy and unpredicted side effect, respectively. Herein, a strategy to enhance the migration efficacy of MSCs to inflamed joints via an inflammation‐mediated education process is demonstrated. To reinforce the limited anti‐inflammatory activity of MSCs, gold nanostar loaded with triamcinolone is conjugated to MSC. Furthermore, near‐infrared laser‐assisted photothermal therapy (PTT) induced by gold nanostar significantly elevates the anti‐inflammatory efficacy of the developed drugs, even in advanced stage arthritis model. An immunological regulation mechanism study of PTT is first suggested in this study; the expression of the interleukin 22 receptor, implicated in the pathogenesis of arthritis, is downregulated in T lymphocytes by PTT, and Th17 differentiation from naïve CD4 T cell is inhibited. Collectively, inflammation‐targeting MSCs conjugated with triamcinolone‐loaded gold nanostar (Edu‐MSCs‐AuS‐TA) promote the repolarization of macrophages and decrease neutrophil recruitment in joints. In addition, Edu‐MSCs‐AuS‐TA significantly alleviate arthritis‐associated pain, improve general locomotor activity, and more importantly, induce cartilage regeneration even for severe stages of arthritis model.
- 22 December 2023
- Published by Wiley in Advanced Materials
- Vol. 36 (11) , e2304333
Inflammation‐Targeting Mesenchymal Stem Cells Combined with Photothermal Treatment Attenuate Severe Joint Inflammation
Current clinical therapeutic efficacy for the treatment of osteo‐ and rheumatoid‐arthritis is obviously limited. Although mesenchymal stem cells (MSCs) are considered as a source of promising regenerative therapy, un‐modified or genetically engineered MSCs injected in vivo restrict their clinical utility because of the low drug efficacy and unpredicted side effect, respectively. Herein, a strategy to enhance the migration efficacy of MSCs to inflamed joints via an inflammation‐mediated education process is demonstrated. To reinforce the limited anti‐inflammatory activity of MSCs, gold nanostar loaded with triamcinolone is conjugated to MSC. Furthermore, near‐infrared laser‐assisted photothermal therapy (PTT) induced by gold nanostar significantly elevates the anti‐inflammatory efficacy of the developed drugs, even in advanced stage arthritis model. An immunological regulation mechanism study of PTT is first suggested in this study; the expression of the interleukin 22 receptor, implicated in the pathogenesis of arthritis, is downregulated in T lymphocytes by PTT, and Th17 differentiation from naïve CD4 T cell is inhibited. Collectively, inflammation‐targeting MSCs conjugated with triamcinolone‐loaded gold nanostar (Edu‐MSCs‐AuS‐TA) promote the repolarization of macrophages and decrease neutrophil recruitment in joints. In addition, Edu‐MSCs‐AuS‐TA significantly alleviate arthritis‐associated pain, improve general locomotor activity, and more importantly, induce cartilage regeneration even for severe stages of arthritis model.